Switch theme
Sign up to access all valuation multiples
Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.
1970
473
Last FY Revenue $185M
Last FY EBITDA $35.3M
$504M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Synmosa Biopharma achieved revenue of $185M and an EBITDA of $35.3M.
Synmosa Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Synmosa Biopharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $185M | XXX | XXX | XXX |
| Gross Profit | XXX | $80.1M | XXX | XXX | XXX |
| Gross Margin | XXX | 43% | XXX | XXX | XXX |
| EBITDA | XXX | $35.3M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 19% | XXX | XXX | XXX |
| EBIT | XXX | $24.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | 13% | XXX | XXX | XXX |
| Net Profit | XXX | $22.8M | XXX | XXX | XXX |
| Net Margin | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | $43.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Synmosa Biopharma's stock price is TWD 34 (or $1).
Synmosa Biopharma has current market cap of TWD 15.6B (or $519M), and EV of TWD 15.1B (or $504M).
See Synmosa Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $504M | $519M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Synmosa Biopharma has market cap of $519M and EV of $504M.
Synmosa Biopharma's trades at 2.7x EV/Revenue multiple, and 14.3x EV/EBITDA.
Equity research analysts estimate Synmosa Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Synmosa Biopharma's P/E ratio is not available.
See valuation multiples for Synmosa Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $519M | XXX | $519M | XXX | XXX | XXX |
| EV (current) | $504M | XXX | $504M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 14.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 20.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 22.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 29.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSynmosa Biopharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Synmosa Biopharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Synmosa Biopharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Synmosa Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Synmosa Biopharma acquired XXX companies to date.
Last acquisition by Synmosa Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Synmosa Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Synmosa Biopharma founded? | Synmosa Biopharma was founded in 1970. |
| Where is Synmosa Biopharma headquartered? | Synmosa Biopharma is headquartered in Taiwan. |
| How many employees does Synmosa Biopharma have? | As of today, Synmosa Biopharma has 473 employees. |
| Is Synmosa Biopharma publicy listed? | Yes, Synmosa Biopharma is a public company listed on ROCO. |
| What is the stock symbol of Synmosa Biopharma? | Synmosa Biopharma trades under 4114 ticker. |
| When did Synmosa Biopharma go public? | Synmosa Biopharma went public in 2003. |
| Who are competitors of Synmosa Biopharma? | Similar companies to Synmosa Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Synmosa Biopharma? | Synmosa Biopharma's current market cap is $519M |
| Is Synmosa Biopharma profitable? | Yes, Synmosa Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
